Capricor Therapeutics (CAPR) Non-Current Deffered Revenue (2014 - 2023)

Capricor Therapeutics' (CAPR) quarterly Non-Current Deffered Revenue came in at $953470.0 in Q3 2023, down 90.32% year-on-year from $9.8 million in Q3 2022, and down 70.5% quarter-over-quarter from $3.2 million in Q2 2023.

Capricor Therapeutics (CAPR) Non-Current Deffered Revenue (2014 - 2023) Analysis & Trends

Capricor Therapeutics' Non-Current Deffered Revenue history runs 4 years deep, the most recent figure standing at $953470.0 for Q3 2023.

  • On a quarterly basis, Non-Current Deffered Revenue fell 90.32% year-over-year to $953470.0 in Q3 2023; TTM through Sep 2023 was $953470.0, a 90.32% decrease from a year earlier, with the FY2022 full-year figure at $9.5 million, changed N/A from the prior year.
  • Non-Current Deffered Revenue fell to $953470.0 in Q3 2023 per CAPR's latest filing, from $3.2 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $20.3 million in Q1 2022 and bottomed at $953470.0 in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 225.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Capricor Therapeutics 457.86 Mn 457.86 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2023 953,470.00
Jun 30, 2023 3.23 Mn
Mar 31, 2023 5.45 Mn
Dec 31, 2022 9.47 Mn
Sep 30, 2022 9.85 Mn
Jun 30, 2022 14.30 Mn
Mar 31, 2022 20.30 Mn
Dec 31, 2015 911,458.00
Sep 30, 2015 1.82 Mn
Jun 30, 2015 2.73 Mn
Mar 31, 2015 3.12 Mn
Dec 31, 2014 4.17 Mn
Sep 30, 2014 5.21 Mn
Jun 30, 2014 6.25 Mn
Mar 31, 2014 7.29 Mn